Intralipid Versus SMOFlipid in HPN Patients

Exclusion Criteria

• •Age less than 18 years
• •Pregnant and lactating women
• •Failure to provide consent
• •Patients with underlying liver dysfunction (defined as liver function studies equal to or more than 2 times upper limit of normal) or pathology as determined by primary investigator
• •Patients with active malignancy
• •Patients who are deemed to be on HPN for less than three months
• •Patients who have previous proven addiction and dependence to alcohol/ heavy alcohol AND consumption/active use reported during last 12 months.
• •Known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the active ingredients or excipients in Smoflipid
• •Patients who will not be managed by the Mayo Clinic HPN team
• •Patients who have active infection (as determined by the clinician) at the time of enrollment.
• •Patients who have received Smoflipid greater than 4 weeks in the last 12 months prior to enrollment.
• •Patients who have been on TPN greater than 4 weeks in the last 12 months prior to enrollment.
• •Enrolled in another interventional study.
• •Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides more than 1,000 mg/dL.